In discussion with Dr. Pamela Kunz, covering the Gastroenterology ASCO 2024 meeting highlights from Community Oncology perspective. We covered 3 important practice informing studies from GI ASCO with Dr. Kunz:
- CheckMate 8HW: Nivolumab plus ipilimumab vs chemotherapy as first-line (1L) treatment for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer
- EMERALD-1: A phase 3, randomized, placebo-controlled study of transarterial chemoembolization combined with durvalumab with or without bevacizumab in participants with unresectable hepatocellular carcinoma eligible for embolization
- NETTER-2: [177Lu]Lu-DOTA-TATE in newly diagnosed patients with advanced grade 2 and grade 3, well-differentiated gastroenteropancreatic neuroendocrine tumors
#GI #ASCO #HCC #Colon #Cancer #NET #Neuroendocrine #2024 #oncology #oncbrothers
Website: [ Ссылка ]
Twitter: [ Ссылка ]
Contact us at info@oncbrothers.com
Dual checkpoint inhibitors for MSI high colorectal cancer
Теги
canceroncologychemotherapytherapyguidelinesnccnsummaryOncBrothersbrothersHighlightsOncrohitgosainrahulvideoabtractsocietyamericanoncdoctordr.healthcaremedicinemedicaloncbrotherspracticechangingmalignancymalignantchemoprognosisstagetdxdfdaapprovalcommunityoncologistoncoligistschiefassociatectascoesmokeynotepembrolizumabgi2024emeraldnivolumabipilimumabnetneuroendocrinepamelakunzyalehepatocellularcarcinomagastriccolonmsidmmrlutetiumtace
